Newswise
Cure8 news brief
Pill Shows Promise for Patients With Ulcerative Colitis
Medications
Abdominal Pain
Anemia
Malnutrition
Phase 2 clinical trial
Adult patients
Patients On Biologics
Clinicians
Why This Matters
An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.
Who Should Pay Attention
Adults with moderate-to-severe ulcerative colitis, patients who have failed prior biologics, clinicians who manage IBD, and researchers in IBD drug development.
Study Snapshot
Story typeResearch news
Evidence typePress release
Source depthMetadata only
What To Know
This news reports Phase IIb clinical-trial results indicating icotrokinra, an oral IL-23–targeting medication, showed benefit versus placebo in moderate-to-severe ulcerative colitis and worked in some patients who previously failed biologics. The study’s primary assessment was at 12 weeks with continued remission reported through 28 weeks.
The medication is already FDA-approved for plaque psoriasis; this trial is testing a new indication (ulcerative colitis). The study was funded by Johnson & Johnson and published in a peer-reviewed journal; disclosures by authors are listed in the article.
If you have ulcerative colitis, this could expand future oral treatment options that target IL-23, but Phase IIb results are preliminary and further larger Phase III studies and regulatory review would be needed before routine clinical use for UC.
Keep In Mind
These are Phase IIb trial results reported in a news release summarizing a New England Journal of Medicine publication; Phase III trials and regulatory review are typically required before a new treatment becomes widely available for UC. The study was funded by the drug maker (Johnson & Johnson), and author disclosures are reported.
Source Details
Review the original publication for the complete reporting, methods, and context.
Press release
Evidence type derived from source or registry metadata.
PublicationNewswise
PublisherNewswise MedNews RSS
AuthorsCedars-Sinai
Indexed viaNewswise
Source typeResearch news
PublishedOct 15, 2026, 8:20 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Relieving IBD with duvakitug
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
A new biologic (duvakitug) targeting TL1A showed higher clinical remission at 14 weeks than placebo in a phase 2b trial of adults with moderately to severely active ulcerative colitis, which could expand future treatment...
Efficacy of Empagliflozin in Patients with Mild-to-Moderate Ulcerative Colitis: A Randomized Controlled Pilot Study.
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...